Date: 2014-09-07
Type of information: Fundraising
Company: Cardiorentis (Switzerland)
Investors: HealthCare Royalty Partners (USA)
Amount: € 45 million
Funding type: fundraising
Planned used: The proceeds will be used to finance Cardiorentis’ registration program for the natriuretic peptide ularitide in acute heart failure.
The TRUE-AHF Phase III trial was initiated in August 2012. It is led by the international principal investigator Milton Packer, M.D., University Texas, Southwestern Medical Center in Dallas, Texas and includes over 200 centers across the U.S., Europe, Canada and Latin America.TRUE-AHF is an event driven trial, which may enroll up to 4,000 patients with acute heart failure. There are two
co-primary endpoints. The first is a composite endpoint for acute heart failure which assesses a patient’s symptoms and persistent or worsening heart failure within the first 48 hours after treatment initiation. The second co-primary endpoint is cardiovascular mortality.
Others: * On September 17, 2014, Cardiorentis AG, a privately held biopharmaceutical company, announced that it has entered into a €45 million financing agreement with HealthCare Royalty Partners, a U.S. based healthcare investment firm. The proceeds will be used to finance the Company’s registration program for the natriuretic peptide ularitide in acute heart failure.
Therapeutic area: Cardiovascular diseases
